MOTS-c
What We've Seen in Practice, and What the Research Says
MOTS-c is one of the more interesting molecules in this whole field, because your body already makes it. It is a tiny peptide produced inside your mitochondria, the parts of your cells that turn food and oxygen into energy, and it acts as a kind of messenger, telling your muscles and the rest of your body how to handle energy and blood sugar. Your own level of it rises when you exercise and falls as you age. In a real sense, it is part of the machinery that makes exercise good for you.
It was also, for a stretch of years, one of our favorite peptides to work with. Dr. Koniver used to reach for it often, particularly for people focused on fitness and body composition, and he has been open about missing it since it left the regular toolkit. That is the honest shape of this page: a peptide we genuinely valued, a research base that is strong in the laboratory and still early in people, and a regulatory story that went away and has recently started to come back.
Below we separate what we saw in our own practice from what the published science actually shows, and we keep the two clearly labeled.
.svg)
What we've seen in practice
Of the mitochondrial peptides, MOTS-c was Dr. Koniver's favorite. He describes it as the stronger, fitter, faster peptide: something that helped people with body composition and physical fitness, and helped them feel stronger and in better athletic shape. What he found most interesting was a little less tangible than that. Beyond the physical changes, he felt MOTS-c helped with energy and with the motivation to actually want to train. For a peptide, that combination was unusual and it is a large part of why he liked it.
We used it in a few ways. Most often we paired it with NAD, which fits how MOTS-c works, since both are tied to how the mitochondria make and manage energy. We gave it by injection on a flexible schedule, and we also used it intravenously, adding it to saline and running it in after an NAD infusion. It sat within a small family of mitochondrial peptides we work with, alongside humanin, which we think of more on the longevity and repair side, and SS-31, which supports the mitochondrial membrane.
Then it went away. MOTS-c was pulled by the FDA in the fall of 2023, along with a number of other peptides, and we lost access to it. Dr. Koniver has been candid that he missed it and hoped it would come back. As it happens, the regulatory picture has since moved in its favor: in April 2026 MOTS-c was withdrawn from the restricted Category 2 list, and in July 2026 an FDA advisory committee voted to recommend it. The regulatory section below has the current status in full.
MOTS-c at a glance
A tiny peptide your own mitochondria make and release into the blood, where it signals to muscle and other tissue about how to use energy and glucose[1]
.svg)
Metabolic health and insulin sensitivity, the body's response to exercise, and age-related metabolic decline[1, 2]
.svg)
Strong laboratory and animal research, consistent human observational data (levels fall with age, rise with exercise), and one early human trial of a modified version; no large trials of the natural peptide yet[1, 2, 4]
.svg)
By subcutaneous injection in the research literature; in our past practice, also intravenously with NAD
.svg)
16 amino acids (MRWQEMGYIFYPRKLR); formula C101H152N28O22S2, about 2,174.6 g/mol; encoded inside the mitochondrial 12S rRNA gene[5]
Not FDA-approved; restricted in the 2023 review, then withdrawn from Category 2 in April 2026 and recommended by an FDA advisory committee in July 2026; prohibited in sport by WADA
One of Dr. Koniver's favorites for fitness and body composition, paired with NAD; pulled in 2023. See what we've seen in practice above
The two pink beads are the methionines (positions 1 and 6) that make the peptide sensitive to oxidation.
Where MOTS-c comes from
For a long time, the small circle of DNA inside our mitochondria was thought to code for only a handful of things needed for energy production. MOTS-c changed that picture. In 2015, researchers reading the mitochondrial 12S rRNA gene found a short hidden instruction inside it that the cell copies out, ships from the mitochondria, and translates into this 16-amino-acid peptide. It was one of the first clear examples of the mitochondria sending a protein signal to the rest of the body, which is why MOTS-c is often called a mitochondrial hormone.
That origin is the interesting part and also the part that is easy to overstate. Because MOTS-c is made by the mitochondria and rises with exercise, it gets described as a way to bottle the benefits of working out. The biology genuinely points in that direction. What is still being worked out is how much of that translates when the peptide is given as a therapy in people, and we keep that distinction front and center on this page.
MOTS-c released into the blood
AMPK (the cell's energy sensor)
Glucose uptake up, fat burning up
Exercise raises the body's own MOTS-c; age and inactivity lower it.
How it works
.svg)
MOTS-c's primary action is to activate AMPK, a master regulator cells use to sense and balance energy. This is the same pathway the metabolic drug metformin works through, a well-understood mechanistic anchor.[1]
.svg)
Through AMPK, MOTS-c helps skeletal muscle pull in glucose and burn fat, along a route that does not require insulin to open the door. In animal models this improves insulin sensitivity at the muscle level.[1]
.svg)
MOTS-c is not static. Exercise raises the amount in working muscle sharply, and levels decline with age and inactivity, tracking the gradual loss of metabolic flexibility.[2]
The laboratory story is strong and the human story is still early, and we treat it that way [1,4].
What the research shows
The foundation for MOTS-c is solid animal and laboratory work. The discovery study showed that giving MOTS-c to mice on a high-fat diet prevented the weight gain and insulin resistance the diet would normally cause [1]. A later study framed MOTS-c as an exercise signal in its own right: it rose with exertion, improved physical capacity, and pushed back against age-related decline in animals, with supporting human data showing muscle levels climbing sharply after exercise [2]. Alongside these, observational studies in people have repeatedly found that the body's own MOTS-c falls with age and runs lower in people with obesity and metabolic disease.
The human treatment data is thinner, and we want to be exact about it. The only interventional human trial to date used a modified, more drug-like version of MOTS-c called CB4211, developed by a company called CohBar. That Phase 1 study, in a group of healthy volunteers and people with fatty liver disease, met its primary safety goal, and the liver-enzyme and blood-sugar readings improved modestly [4]. It did not advance further, and the company later wound down. Importantly, there is no completed trial of the natural MOTS-c peptide itself. So the honest summary is a strong mechanistic and animal case, encouraging early human signals, and no large human outcome trials for either version.
Metabolic health and insulin sensitivity
Animal models plus human observational data
Improves glucose handling and insulin sensitivity via AMPK; own levels track metabolic health
Strong preclinically; human data is correlational [1]
Exercise response and aging
Animal models with supporting human exercise data
Rises with exercise, improves physical capacity, counters age-related decline in animals
Compelling, still preclinical for outcomes [2]
Early human trial
One Phase 1 of a modified analogue (CB4211)
Met its safety endpoint; modest metabolic improvements
Did not progress past Phase 1 [4]
Body composition and weight loss in people
-
-
Not established; we do not use it as a weight-loss peptide
How strong is the evidence
Chips read left to right from stronger to weaker. Green marks our own clinical observation, which is experience, not a trial.
The human safety information we have comes from that single Phase 1 trial of the modified analogue, CB4211, where there were no serious adverse events and the most common issue was a reaction at the injection site [4]. That is a reasonable early signal, but it is a narrow base. Because there is no completed trial of the natural peptide, the formal long-term safety, pharmacokinetic, and cancer-related studies simply have not been done, and we do not pretend otherwise.
The most practical caution is specific and worth stating clearly. Because MOTS-c works on the same energy-sensing pathway as metformin, using it alongside insulin, GLP-1 medications, or other blood-sugar-lowering treatments could lower glucose more than intended, so that combination needs careful clinical coordination. As with the other peptides we work with, we would not consider it for anyone with active or previous cancer, or during pregnancy or breastfeeding, and it is off the table for anyone competing in a WADA-regulated sport. Any use belongs under physician supervision with appropriate lab monitoring, not as a self-directed experiment.
Regulatory status
Regulatory information current as of 12 August 2026. This is a summary, not legal or medical advice, and status can change.
Placed on the FDA's restricted Category 2 list, which closed the regulated compounding channel. This is when it left our toolkit. The move was regulatory, not a safety recall we made.
Withdrawn from Category 2 (nominated but withdrawn), lifting that specific restriction, so standard 503A and 503B pharmacy rules now apply.
An FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend MOTS-c. That is a recommendation and a favorable signal, not a final rule, and we treat it as such.
As a medicine,
worldwide
Not approved anywhere for these uses; it remains a research peptide.
United States
Not FDA-approved. No longer on the Category 2 restricted list, and recommended by the advisory committee in July 2026. Because this area is moving, confirm current status directly.
Sport (WADA)
Prohibited
Prohibited at all times, in and out of competition, as a metabolic modulator (AMPK activator). Detectable. Not for anyone competing in a WADA-regulated sport. [6]
Everywhere else
Availability and legal status vary by country and change over time; confirm the current position before considering it.
Regulatory information current as of 12 August 2026. Verify status at publication.
MOTS-c, answered plainly
It is a small peptide your own mitochondria make and release into your bloodstream, where it acts as a signal that helps your muscles and other tissues manage energy and glucose. Its level naturally rises with exercise and falls with age.[1]
It was pulled from the compounding channel when the FDA placed it on the restricted Category 2 list in late 2023, so we lost access to it. The restriction on it was lifted in April 2026 and an FDA advisory committee recommended it in July 2026. Its availability now depends on where that regulatory process settles, so anyone considering it should confirm the current status.
In our practice, Dr. Koniver valued it mainly for fitness and body composition, and for a boost in energy and the motivation to train. We often paired it with NAD, including intravenously. We did not treat it as a weight-loss shortcut, and the research does not support it as one.
The human safety data is limited to one early trial of a modified version, which looked reasonable but is a narrow base, and the natural peptide has no completed trial. The main practical caution is that it can add to the blood-sugar-lowering effect of medications like insulin or GLP-1 drugs, so it needs medical oversight [4].
No. It is prohibited by WADA at all times and is detectable on testing. The regulatory section above has the specifics [6].
Related in this directory
References
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID 33473109.
- Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016. PMID 27216708.
- CohBar, Inc. Positive topline results from the Phase 1a/1b study of CB4211 (a modified MOTS-c analogue) for NASH and obesity, 2021. The program did not advance past Phase 1; the native MOTS-c peptide has no completed human trial.
- PubChem, National Library of Medicine. MOTS-c, CID 146675088: C101H152N28O22S2, 2,174.6 g/mol, CAS 1627580-64-6.
- World Anti-Doping Agency. The Prohibited List; MOTS-c prohibited at all times as a metabolic modulator, effective 2024 onward.
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. MOTS-c is not approved by the FDA or any national health authority for the metabolic, fitness, or anti-aging uses discussed, and is prohibited in competitive sport. Statements describing how Dr. Koniver and the Koniver Wellness team have used MOTS-c reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Nothing here is a substitute for consultation with a qualified healthcare provider. Peptide therapy at Koniver Wellness is provided under physician supervision after appropriate screening, and the availability of any given peptide depends on its regulatory and supply status.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.